Less than a year after raising $72.6m in its series A round, Aerovate Therapeutics has gone public following an IPO worth more than $121m.

Aerovate Therapeutics, a US-based pulmonary disease treatment developer backed by spinout-focused venture capital firm Osage University Partners, went public yesterday following an initial public offering that raised more than $121m.
The company issued more than 8.68 million shares priced at $14 in its upsized offering on the Nasdaq Global Market, where it has listed under the ticker symbol AVTE. Shares hit a $29.43 peak on the first day of trading and are worth $22.83 as of the…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?
Thierry Heles

Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).